NCT05003622View on ClinicalTrials.gov

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

May 6, 2022

Study Completion Date

May 6, 2022

Conditions
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Interventions
DRUG

Encorafenib

oral capsule

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY